Intravenous Compared to Oral Busulfan with Cyclophosphamide for Autologous Hematopoietic Progenitor Cell Transplant Conditioning for Plasma Cell Myeloma

被引：0
|
作者：
Sobecks, Ronald [1 ]
Rybicki, Lisa [2 ]
Dean, Robert M. [1 ]
Abounader, Donna [1 ]
Andresen, S. [1 ]
Hien Duong [1 ]
Reu, Fred [1 ]
Bolwell, Brian [1 ]
Copelan, Ed [1 ]
Kalaycio, Matt E. [1 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA
[2] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2013年 / 19卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2012.11.192
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
152
引用
收藏
页码：S190 / S190
页数：1
相关论文
共 50 条
  • [21] Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance
    Manson, G. V.
    Campagnaro, E.
    Balog, A.
    Kaplan, D.
    Sommers, S. R.
    Fu, P.
    Rajkumar, S. V.
    Lazarus, H. M.
    BONE MARROW TRANSPLANTATION, 2012, 47 (09) : 1212 - 1216
  • [22] Progenitor cell transplantation (PCT) in children with a conditioning regimen of busulfan, cyclophosphamide and etoposide.
    Mustafa, MM
    El Solh, H
    Ayas, M
    Al-Mahr, M
    Al-Jefri
    BLOOD, 1998, 92 (10) : 353B - 353B
  • [23] Factors that predict successful remobilization after autologous hematopoietic progenitor cell transplant (aHCT) for multiple myeloma
    Papanikolaou, Xenofon Dimitrios
    Rosenbaum, Eric
    Tyler, Lisa
    Barlogie, Bart
    Cottler-Fox, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Oral busulfan and cyclophosphamide conditioning regimen for autologous stem cell transplants in patients with Non-Hodgkin Lymphoma.
    Fernandez, HF
    Goodman, MS
    Pandite, L
    Cassileth, PA
    BLOOD, 1999, 94 (10) : 356B - 356B
  • [25] Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation
    Hassan, Moustapha
    Andersson, Borje S.
    PHARMACOGENOMICS, 2013, 14 (01) : 75 - 87
  • [26] Association of Busulfan and Cyclophosphamide Conditioning with Sleep Disorders after Hematopoietic Stem Cell Transplantation
    Faulhaber, Gustavo A. M.
    Furlanetto, Tania W.
    Astigarraga, Claudia C.
    Moser Filho, Humberto Luiz
    Paludo, Angela Paula
    Silla, Lucia M. R.
    ACTA HAEMATOLOGICA, 2010, 124 (02) : 125 - 128
  • [27] Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning
    Zao, Jamie H.
    Schechter, Tal
    Liu, Wenchao Jessica
    Gerges, Sandra
    Gassas, Adam
    Egeler, R. Maarten
    Grunebaum, Eyal
    Dupuis, L. Lee
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (08) : 1471 - 1478
  • [28] THIOTEPA BUSULFAN CYCLOPHOSPHAMIDE, A TOXIC CONDITIONING FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CENTRAL NERVOUS SYSTEM LYMPHOMA: REMISSION OR INFECTION?
    Debureaux, P-E
    Royer, B.
    Gruson, B.
    Votte, P.
    Joris, M.
    Damaj, G. L.
    Marolleau, J-P
    Delphine, L.
    HAEMATOLOGICA, 2017, 102 : 689 - 690
  • [29] Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma
    Bains, Tarunpreet
    Chen, Andy I.
    Lemieux, Andrew
    Hayes-Lattin, Brandon M.
    Leis, Jose F.
    Dibb, William
    Maziarz, Richard T.
    LEUKEMIA & LYMPHOMA, 2014, 55 (03) : 583 - 587
  • [30] Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma
    Toor, AA
    Ayers, J
    Strupeck, J
    Parthasarathy, M
    Creech, S
    Rodriguez, T
    Stiff, PJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (06) : 769 - 776
12345